Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China

Adult Clinical Trial

Official title:

Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in 5 Large Cities in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00478829
• Other study ID #: 0600B2-4417
• Status: Completed
• Phase: N/A
• First received: May 24, 2007
• Last updated: December 4, 2007
• Start date: April 2007
• Est. completion date: July 2007

Study information

• Verified date: December 2007
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Objectives: Primary: To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.

Secondary:

• To estimate gender- and age-specific prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.

• To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings such as departments of neurology, gastroenterology, cardiology, and gynecology.

• To describe the recognition and treatment rate by treating physicians as depression and/or anxiety for outpatients in the general health care settings in China.

Description:

This study is designed to investigate the status of identifying depression and/or anxiety disorder with somatic symptoms in general hospitals in China. The study will generate valuable information to the medical community; therefore the early and vigorous treatment is possible. It's in line with China government authorities' target to increase the recognition rate of depression and/or anxiety in primary care settings to more than 50% by the end of 2010. The study will also help to identify specific diagnosis and treatment patterns for depressive / anxious patients and their comorbid conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8000
• Est. completion date: July 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Main Inclusion Criteria:

• Greater than or equal to 18 years.

• Consecutive general internal medical outpatients attending the selected general hospitals in the investigate days(Department of neurology, gastrointestinal, cardiology and gynecology).

• Informed consent obtained for all patients who will undergo a standardized diagnostic assessment by specialized psychiatrists.

Main Exclusion Criteria:

• Patients who have been screened on a previous visit.

• Patients who are unable to complete the survey because of mental or physical incapacity.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Adult

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

China,